Vertex Pharmaceuticals (VRTX) EBIT (2016 - 2025)
Historic EBIT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.
- Vertex Pharmaceuticals' EBIT rose 1753.41% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 billion, marking a year-over-year increase of 189188.49%. This contributed to the annual value of $4.2 billion for FY2025, which is 189188.49% up from last year.
- According to the latest figures from Q4 2025, Vertex Pharmaceuticals' EBIT is $1.2 billion, which was up 1753.41% from $1.2 billion recorded in Q3 2025.
- In the past 5 years, Vertex Pharmaceuticals' EBIT registered a high of $1.2 billion during Q4 2025, and its lowest value of -$3.5 billion during Q2 2024.
- Its 5-year average for EBIT is $743.1 million, with a median of $1.0 billion in 2022.
- As far as peak fluctuations go, Vertex Pharmaceuticals' EBIT skyrocketed by 301899.74% in 2022, and later tumbled by 44242.99% in 2024.
- Over the past 5 years, Vertex Pharmaceuticals' EBIT (Quarter) stood at $877.7 million in 2021, then increased by 17.75% to $1.0 billion in 2022, then dropped by 4.35% to $988.5 million in 2023, then grew by 3.79% to $1.0 billion in 2024, then increased by 17.53% to $1.2 billion in 2025.
- Its EBIT stands at $1.2 billion for Q4 2025, versus $1.2 billion for Q3 2025 and $1.2 billion for Q2 2025.